Abbott Laboratories (NYSE:ABT) Stock Price Expected to Rise, Barclays Analyst Says

Abbott Laboratories (NYSE:ABT) had its price target hoisted by equities researchers at Barclays from $142.00 to $144.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the healthcare product maker’s stock. Barclays‘s price objective would indicate a potential upside of 39.75% from the stock’s current price.

Several other research analysts have also weighed in on ABT. Sanford C. Bernstein lowered their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Argus lowered their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Raymond James Financial lowered their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Evercore lowered their target price on shares of Abbott Laboratories from $138.00 to $134.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Leerink Partners lowered their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $134.58.

Abbott Laboratories Trading Up 1.2%

Shares of ABT traded up $1.21 during mid-day trading on Wednesday, reaching $103.04. The stock had a trading volume of 618,157 shares, compared to its average volume of 11,087,690. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a 52-week low of $100.88 and a 52-week high of $139.06. The business’s fifty day moving average is $109.22 and its 200 day moving average is $120.47. The firm has a market cap of $179.46 billion, a price-to-earnings ratio of 27.65, a P/E/G ratio of 1.64 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the firm posted $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Insider Buying and Selling at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Institutional Trading of Abbott Laboratories

Several hedge funds have recently added to or reduced their stakes in ABT. J. Stern & Co. LLP raised its holdings in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Norges Bank acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $2,938,892,000. Invesco Ltd. raised its holdings in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after acquiring an additional 4,713,135 shares in the last quarter. Ninety One UK Ltd acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $336,815,000. Finally, Vanguard Group Inc. raised its holdings in Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Dividend / value story highlighted — multiple recent pieces frame ABT as a “dividend king on sale,” drawing attention from income and value investors who may see the pullback as a buying opportunity. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Positive Sentiment: Major sell‑side firms keep constructive stances — Evercore ISI and BTIG trimmed price targets but maintained positive/outperform ratings, leaving analysts’ views supportive even after modest PT adjustments (PT still above current levels), which can limit downside and attract buyers on dips. Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
• Neutral Sentiment: Market opportunity in digital health supports longer-term demand — a new industry report cites growth in digital health monitoring devices and lists Abbott among key players, underscoring exposure to a growing end market but with benefits realized over the medium term. Digital Health Monitoring Devices Market Report 2026-2030
• Negative Sentiment: Recent share‑price weakness and fading momentum highlighted — valuation and analysis pieces note ABT is down materially over recent months (single‑digit to double‑digit pullbacks), flagging momentum concerns that may pressure sentiment and prompt further selling or analyst scrutiny. Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness
• Negative Sentiment: Minor analyst estimate cut from Erste — Erste Group trimmed its FY2027 EPS projection very slightly (from $6.25 to $6.24). The change is minimal, but it adds to the recent string of adjustments and cautious tone from some analysts.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.